{"id":"NCT02243293","sponsor":"AbbVie","briefTitle":"A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotypes 2, 3, 4, 5 or 6 Infection","officialTitle":"A Randomized, Open-Label, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotypes 2, 3, 4, 5 or 6 Infection (SURVEYOR-II)","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2014-09-19","primaryCompletion":"2016-10-25","completion":"2017-02-23","firstPosted":"2014-09-17","resultsPosted":"2017-10-02","lastUpdate":"2021-07-30"},"enrollment":694,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Hepatitis C","Hepatitis C Virus"],"interventions":[{"type":"DRUG","name":"ABT-493","otherNames":["glecaprevir"]},{"type":"DRUG","name":"ABT-530","otherNames":["pibrentasvir"]},{"type":"DRUG","name":"ribavirin (RBV)","otherNames":[]},{"type":"DRUG","name":"ABT-493/ABT-530","otherNames":["ABT-493 also known as glecaprevir","ABT-530 also known as pibrentasvir","MAVYRET"]}],"arms":[{"label":"Arm A","type":"EXPERIMENTAL"},{"label":"Arm B","type":"EXPERIMENTAL"},{"label":"Arm C","type":"EXPERIMENTAL"},{"label":"Arm D","type":"EXPERIMENTAL"},{"label":"Arm E","type":"EXPERIMENTAL"},{"label":"Arm F","type":"EXPERIMENTAL"},{"label":"Arm G","type":"EXPERIMENTAL"},{"label":"Arm H","type":"EXPERIMENTAL"},{"label":"Arm I","type":"EXPERIMENTAL"},{"label":"Arm J","type":"EXPERIMENTAL"},{"label":"Arm K","type":"EXPERIMENTAL"},{"label":"Arm L","type":"EXPERIMENTAL"},{"label":"Arm M","type":"EXPERIMENTAL"},{"label":"Arm N","type":"EXPERIMENTAL"},{"label":"Arm O","type":"EXPERIMENTAL"},{"label":"Arm P","type":"EXPERIMENTAL"},{"label":"Arm Q1","type":"EXPERIMENTAL"},{"label":"Arm Q2","type":"EXPERIMENTAL"},{"label":"Arm R1","type":"EXPERIMENTAL"},{"label":"Arm R2","type":"EXPERIMENTAL"},{"label":"Arm S1","type":"EXPERIMENTAL"},{"label":"Arm S2","type":"EXPERIMENTAL"}],"summary":"The purpose of this phase 2/3, open-label, multipart, multicenter study was to evaluate the efficacy, and safety of co-administration of ABT-493 and ABT-530 with and without ribavirin (RBV) in chronic HCV genotype 2 (GT2-), genotype 3 (GT3-), genotype 4 (GT4), genotype 5 (GT5-), or genotype 6 (GT6-) infected participants with or without cirrhosis.","primaryOutcome":{"measure":"Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12)","timeFrame":"12 weeks after the last actual dose of study drug","effectByArm":[{"arm":"Arm A","deltaMin":96,"sd":null},{"arm":"Arm B","deltaMin":100,"sd":null},{"arm":"Arm C","deltaMin":100,"sd":null},{"arm":"Arm D","deltaMin":93.3,"sd":null},{"arm":"Arm E","deltaMin":93.3,"sd":null},{"arm":"Arm F","deltaMin":93.5,"sd":null},{"arm":"Arm G","deltaMin":83.3,"sd":null},{"arm":"Arm J","deltaMin":98.1,"sd":null},{"arm":"Arm L","deltaMin":94.3,"sd":null},{"arm":"Arm O","deltaMin":96.4,"sd":null},{"arm":"Arm P","deltaMin":100,"sd":null},{"arm":"Arm Q1","deltaMin":97.5,"sd":null},{"arm":"Arm Q2","deltaMin":90.9,"sd":null},{"arm":"Arm R1","deltaMin":95.5,"sd":null},{"arm":"Arm R2","deltaMin":95.7,"sd":null},{"arm":"Arm S1","deltaMin":97.9,"sd":null},{"arm":"Arm S2","deltaMin":93.1,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":5},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["28412293","31568620","30977945","30923816","30012435","28951228","27456384"],"seeAlso":["http://rxabbvie.com"]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":25},"commonTop":["Fatigue","Headache","Nausea","Diarrhoea","Upper respiratory tract infection"]}}